Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04515576 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3493269 in Participants With Type 2 Diabetes
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT04515576 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 56 participants.
The verdict
NCT04515576, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the side effects related to LY3493269 in participants with type 2 diabetes. Blood tests will be performed to check concentrations of LY3493269 in the bloodstream. Each enrolled participant will receive LY3493269, dulaglutide, or placebo. The study will last up to approximately 16 weeks for each participant and may include up to 11 visits.
Interventions
- DRUG Placebo
- DRUG Dulaglutide
- DRUG LY3493269
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2020-08-25 |
| Est. Completion | 2021-03-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04515576
The ClinicalTrials.gov registry entry for NCT04515576 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04515576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04515576 about?
NCT04515576 is a clinical study titled "A Study of LY3493269 in Participants With Type 2 Diabetes". The main purpose of this study is to determine the side effects related to LY3493269 in participants with type 2 diabetes. Blood tests will be performed to check concentrations of LY3493269 in the bloodstream. Each enrolled participant will receive LY3493269, dulaglutide, or placebo. The study will ...
What is the current status of trial NCT04515576?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2020-08-25. Estimated completion is 2021-03-09.
What interventions are being tested in trial NCT04515576?
The interventions under investigation include: Placebo (DRUG), Dulaglutide (DRUG), LY3493269 (DRUG).
Who is sponsoring clinical trial NCT04515576?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.